CSF EULAR 2023 PsA Highlights
- No tags were found...
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>EULAR</strong> <strong>2023</strong><br />
Congress Preview<br />
<strong>PsA</strong><br />
Faculty Introduction<br />
Dear Colleagues,<br />
Welcome to this year’s selection of <strong>EULAR</strong> abstracts on <strong>PsA</strong> and my ‘<strong>Highlights</strong>’. We have selected a variety of abstracts<br />
that cover a range of key topics in the management of psoriatic arthritis.<br />
Wednesday starts off with an insightful series of presentations. This includes a discussion by Gonul Hazal Koc on the<br />
determinants of radiographic progression in early <strong>PsA</strong> (OP0065). The Comorbidities in RMD session also features a<br />
presentation by Daniela Di Giuseppe on the comparative effectiveness of biologic and targeted synthetic DMARDs in <strong>PsA</strong>,<br />
stratified by comorbidities (OP0022).<br />
There are two posters of special interest to me on Thursday. This includes the latest comparison of BASDAI and ASDAS<br />
measurement tools by my <strong>CSF</strong> colleague Xenofon Baraliakos (POS0023), as well as another on enthesitis and its impact<br />
on PROs by Dennis McGonagle (POS0027).<br />
Friday features the Treatment in psoriatic arthritis on the move session which promises to be truly interesting, featuring<br />
therapeutic updates on bimekizumab (POS0231), guselkumab (POS0227), and tofacitinib (POS0232). The latest data from<br />
the USRAT registry is also presented, discussing cardiovascular and thromboembolic events before and after the initiation<br />
of first advanced therapy (POS1063).<br />
The Saturday <strong>EULAR</strong> Recommendations session is always important, and this year Laure Gossec presents the<br />
latest Recommendations on the management of <strong>PsA</strong>. This offers a great end to the congress, offering the latest<br />
recommendations for the management of psoriatic arthritis.<br />
Beyond the main scientific programme there are also many interesting satellite symposia. One we suggest is the <strong>CSF</strong>’s<br />
The “Case” for JAK Inhibitors, where I will join my colleagues in discussing the optimisation of JAK inhibitor therapies.<br />
We have highlighted a selection of other symposiums at the end of this brochure.<br />
As always, thank you for your continued support. We hope you have a fantastic time at <strong>EULAR</strong> <strong>2023</strong>!<br />
Kind regards<br />
Professor Peter Nash<br />
Ps. Make sure you get all the insights from this <strong>EULAR</strong> by downloading our other highlights brochures, and if you want to<br />
see the top picks for Lupus head on over to www.lupus-forum.com where you’ll find the top <strong>EULAR</strong> picks and their top<br />
abstracts in the field of lupus therapeutics.<br />
Register for FREE content at<br />
www.cytokinesignalling.com<br />
Follow us at:<br />
Cytokine Signalling Forum<br />
SPONSORSHIP AND UNRESTRICTED<br />
EDUCATIONAL GRANTS FROM<br />
DEVELOPED UNDER<br />
THE AUSPICES OF THE
KEY: H <strong>Highlights</strong> SCIENTIFIC SESSION ORAL SESSION POSTER SESSION ABSTRACT SESSION<br />
Key Presentations<br />
Wednesday, 31 May <strong>2023</strong><br />
16:30–<br />
18:00<br />
OP0022<br />
16:30–<br />
18:00<br />
OP0061<br />
16:30–<br />
18:00<br />
OP0062<br />
OP0065<br />
OP0067<br />
OP0068<br />
COMORBIDITIES IN RMD<br />
Chairs: Patrick Durez and Ioannis Parodis<br />
Comparative effectiveness of biologic and targeted synthetic<br />
DMARDs in psoriatic arthritis according to comorbidities at<br />
treatment start: a Nordic collaborative study based on enriched<br />
clinical registers<br />
Daniela Di Giuseppe<br />
CLINICAL ASPECTS AND TREATMENT<br />
OF AXSPA: EFFECTS AND PREDICTORS<br />
OF EFFECTS<br />
Chairs: Astrid van Tubergen and Alexandre Sepriano<br />
Development of extra-musculoskeletal manifestations in<br />
upadacitinib-treated patients with psoriatic arthritis, ankylosing<br />
spondylitis, or non-radiographic axial spondyloarthritis<br />
Denis Poddubnyy<br />
NEW CLINICAL ASPECTS IN PSORIATIC<br />
ARTHRITIS<br />
Chair: George E. Fragoulis<br />
<strong>EULAR</strong> points to consider for the definition of<br />
clinical and imaging features suspicious for<br />
progression to Psoriatic Arthritis<br />
Alen Zabotti<br />
The determinants of radiographic progression in<br />
early <strong>PsA</strong> patients<br />
Gonul Hazal Koc<br />
Sex differences in perceptions of psoriatic arthritis disease<br />
impact, management and physician interactions: results from<br />
a global patient survey<br />
Lihi Eder<br />
Barriers to overcome in the achievement to the treatment goal<br />
in psoriatic arthritis; central sensitization and neuropathic pain<br />
Servet Akar<br />
Thursday, 01 June <strong>2023</strong><br />
11:15–<br />
12:00<br />
12:00–<br />
13:30<br />
POS0023<br />
POS0027<br />
AXIAL AND PERIPHERAL SPONDYLOARTHRITIS<br />
Chairs: Floris A. van Gaalen and Helena Marzo-Ortega<br />
Management of axial and peripheral spondyloarthritis in <strong>2023</strong><br />
Désirée van der Heijde<br />
CONTEMPORARY CLINICAL TOPICS IN<br />
PSORIATIC ARTHRITIS<br />
Chair: George Bertsias<br />
Performance of BASDAI vs. ASDAS in evaluating<br />
axial involvement in patients with <strong>PsA</strong> treated with<br />
guselkumab: pooled analysis of two phase 3 studies<br />
Xenofon Baraliakos<br />
Individual entheseal points have differential frequency of<br />
involvement and impact on patient reported outcomes in<br />
patients with active psoriatic arthritis: pooled analysis of two<br />
phase 3, randomized, double-blind, placebo-controlled studies<br />
Dennis McGonagle<br />
H<br />
H<br />
H<br />
Friday, 02 June <strong>2023</strong><br />
09:30–<br />
10:30<br />
POS1063<br />
11:15–<br />
12:00<br />
12:00–<br />
13:30<br />
POS0224<br />
POS0225<br />
POS0227<br />
POS0228<br />
POS0231<br />
POS0232<br />
POSTER VIEW 4<br />
Cardiovascular and thromboembolic events in rheumatoid<br />
arthritis and psoriatic arthritis patients over 3 years before<br />
and 3 years after initiation of a first advanced therapy.<br />
data from the university of sherbrooke registry of advanced<br />
therapies (USRAT)<br />
Gilles Boire<br />
HOW TO TREAT PSORIATIC ARTHRITIS<br />
Chair: Denis Poddubnyy<br />
HOT psoriatic arthritis<br />
Laure Gossec<br />
TREATMENT IN PSORIATIC ARTHRITIS ON<br />
THE MOVE<br />
Ann-Sophie De Craemer<br />
Enhanced surveillance for the detection of psoriatic arthritis<br />
in a UK primary care psoriasis population versus usual care:<br />
results at 24 months from the The Total bUrDen Of psoRiasis<br />
(TUDOR) randomised control trial<br />
Neil McHugh<br />
How Well Does Ultrasound-Assessed Synovitis in Reduced<br />
Joint Sets Predict the Response to Secukinumab in Patients<br />
with Active Psoriatic Arthritis and Inadequate Response to<br />
Conventional DMARDs? – Exploratory Results from a Phase<br />
3b Study<br />
Maria-Antonietta D’Agostino<br />
Serum extracellular matrix biomarkers identify response to<br />
guselkumab in psoriatic arthritis: post-hoc analysis from a<br />
phase 3, randomized, double-blind, placebo-controlled study<br />
through 2 years<br />
Signe Holm Nielsen<br />
Minimal important difference (MID), minimal detectable change<br />
(MDC), and disease activity thresholds for two novel composite<br />
instruments (3VAS, 4VAS) in patients with psoriatic arthritis:<br />
pooled analysis of three phase 3 studies<br />
William Tillett<br />
Sustained efficacy and safety of bimekizumab in<br />
patients with active psoriatic arthritis and prior<br />
inadequate response to tumour necrosis factor<br />
inhibitors: results from the phase 3 be complete<br />
study and its open-label extension up to 1 year<br />
Joseph F. Merola<br />
Post-marketing safety surveillance of tofacitinib<br />
over 9 years in patients with rheumatoid arthritis<br />
and psoriatic arthritis<br />
Gerd Rüdiger Burmester<br />
H<br />
H
KEY: H <strong>Highlights</strong> SCIENTIFIC SESSION ORAL SESSION POSTER SESSION ABSTRACT SESSION<br />
Saturday, 03 June <strong>2023</strong><br />
10:30–<br />
11:30<br />
POS1528<br />
POS1533<br />
POS1534<br />
POS1536<br />
POS1537<br />
POS1539<br />
POS1540<br />
POS1541<br />
POS1544<br />
12:00–<br />
13:15<br />
POSTER VIEW 6<br />
Prediction Of Low Disease Activity In Patients With Psoriatic<br />
Arthritis Treated With Secukinumab In Real World – Data From<br />
The German Aquila Study<br />
Uta Kiltz<br />
Bimekizumab Treatment Resulted In Clinically Meaningful<br />
Improvements In The Psoriatic Arthritis Impact Of Disease-12<br />
(Psaid-12) Scores Using Pooled Results From Two Phase 3<br />
Trials In Patients With Psoriatic Arthritis<br />
Laure Gossec<br />
Bimekizumab Maintained Efficacy Responses Through 52 Weeks<br />
In Biologic Disease-Modifying Antirheumatic Drug-Naïve Patients<br />
With Psoriatic Arthritis Who Were Responders At Week 16:<br />
Results From Be Optimal, A Phase 3, Active-Reference Study<br />
Dennis McGonagle<br />
Assessment Of Pain Outcomes In A Phase 2 Trial Of<br />
Deucravacitinib In Patients With Active Psoriatic Arthritis<br />
Philip J Mease<br />
Bimekizumab Efficacy And Safety In Biologic Dmard-Naïve<br />
Patients With Psoriatic Arthritis Was Consistent With Or<br />
Without Methotrexate: 52-Week Results From The Phase 3<br />
Active Reference Study Be Optimal<br />
Frank Behrens<br />
Safety And Efficacy Of Upadacitinib In Patients With Psoriatic<br />
Arthritis And Inadequate Response To Biologics: 3-Year Results<br />
From The Phase 3 Select-Psa 2 Study<br />
Philip J Mease<br />
Early Skin And Early Enthesitis Responses In Psoriatic Arthritis<br />
Patients Treated With Guselkumab Associate With Long-Term<br />
Response: Post Hoc Analysis Through 2 Years Of A Phase 3 Study<br />
Dennis McGonagle<br />
Long-Term Efficacy And Safety Of Upadacitinib In Patients With<br />
Psoriatic Arthritis: 3-Year Results From The Phase 3 Select-<br />
Psa 1 Study<br />
Iain McInnes<br />
Long-Term Safety And Efficacy Of Tofacitinib In Patients<br />
With Psoriatic Arthritis By Prior Biologic Disease-Modifying<br />
Antirheumatic Drug Exposure<br />
Dafna D Gladman<br />
<strong>EULAR</strong> RECOMMENDATIONS SESSION<br />
Chairs: Robert B.M. Landewé and Uta Kiltz<br />
<strong>EULAR</strong>-recommendations on the management of <strong>PsA</strong><br />
Laure Gossec<br />
Satellite Symposia<br />
WEDNESDAY, 31 MAY <strong>2023</strong><br />
18:30–<br />
19:45<br />
18:30–<br />
19:45<br />
18:30–<br />
19:45<br />
Why Benefit: Risk Assessment Should Drive Individualized<br />
Treatment Decisions<br />
Sponsor: AbbVie Chair: Kimme Hyrich<br />
Raising the Bar: Optimizing Outcomes in Spondylarthritis<br />
Sponsor: UCB Chair: Helena Marzo-Ortega<br />
IL-23 in <strong>PsA</strong>: Connecting the Domains of Skin, Gut, and Joint<br />
Sponsor: Janssen Chairs: Dennis McGonagle & Kilian Eyeric<br />
H<br />
THURSDAY, 01 JUNE <strong>2023</strong><br />
08:15–<br />
09:30<br />
08:15–<br />
09:30<br />
08:15–<br />
09:30<br />
17:30–<br />
18:45<br />
17:30–<br />
18:45<br />
17:30–<br />
18:45<br />
17:30–<br />
18:45<br />
Finding the Right Treatment for the Right Patient: What<br />
Similarities and Key Differences Among RA, <strong>PsA</strong> and AxSpA<br />
Determine Treatment Decisions<br />
Sponsor: Lilly Chair: Roberto Caporali<br />
Getting to the Root of <strong>PsA</strong> and axSpA<br />
Sponsor: Novartis Chair: Ennio Lubrano<br />
Tailoring <strong>PsA</strong> Therapy to Fit the Patient – Are Emerging<br />
Therapies Part of Your Collection?<br />
Sponsor: AbbVie Chair: Laure Gossec<br />
Connections Between the Gut, Joint and Spine: Evidence and<br />
Experience with JAK Inhibitors<br />
Sponsor: Pfizer Chair: Sofia Ramiro<br />
The Time is NOW! Aiming for Higher Treatment Targets in <strong>PsA</strong><br />
and AxSpA<br />
Sponsor: UCB Chair: Francesco Ciccia<br />
Moving Closer to Optimal Pain Management and Timing<br />
Intervention in <strong>PsA</strong><br />
Sponsor: Janssen Chair: Carlo Selmi<br />
SpA on the Runway – A Front Row Seat for a Closer Look at<br />
the Latest Trends<br />
Sponsor: AbbVie Chair: Filip van den Bosc<br />
FRIDAY, 02 JUNE <strong>2023</strong><br />
08:15–<br />
09:30<br />
17:30–<br />
18:45<br />
The Great Debate: Force of Habit vs. Innovative Approach in<br />
the Management of Inflammatory Rheumatic Diseases<br />
Sponsor: Lilly Chair: Carlo Selmi<br />
The “Case” for JAK Inhibitors<br />
Sponsor: Lilly Chair: Elena Nikiphorou<br />
Abstract Sessions<br />
RHEUMATOID ARTHRITIS –<br />
NON BIOLOGIC TREATMENT AND SMALL MOLECULES<br />
AB0450<br />
Real-World Use of Jak Inhibitors in Rheumatological Practice<br />
in South London<br />
K. Biddle<br />
SPONDYLOARTHRITIS – TREATMENT<br />
AB0938<br />
AB0957<br />
AB0959<br />
Safety Profile of Bimekizumab at Week 16 In Patients with<br />
Axial Spondyloarthritis and Psoriatic Arthritis: Results from Four<br />
Placebo-Controlled Phase 3 Studies<br />
D. Poddubnyy<br />
Improvements In Patient-Reported Outcomes Among Patients<br />
with Resolution of Enthesitis And/Or Dactylitis: Post Hoc<br />
Analyses from The Keepsake 1 And 2 Trials of Risankizumab<br />
in Patients with Active Psoriatic Arthritis<br />
S. Kwatra<br />
Secukinumab Survival and Associated Demographic<br />
Characteristics in Patients with Spondyloarthritis and Psoriasic<br />
Arthritis in A Real Clinical Setting<br />
M. López I Gómez<br />
PSORIATIC ARTHRITIS – TREATMENT<br />
AB1082<br />
Early Clinical Response as A Predictor of Long-Term<br />
Health-Related Quality of Life Improvements in<br />
Patients with Psoriatic Arthritis and Tnfi-Ir Receiving<br />
Guselkumab (Cosmos)<br />
L. Gossec<br />
H
KEY: H <strong>Highlights</strong> SCIENTIFIC SESSION ORAL SESSION POSTER SESSION ABSTRACT SESSION<br />
AB1084<br />
AB1087<br />
AB1088<br />
AB1089<br />
AB1090<br />
AB1092<br />
AB1093<br />
AB1094<br />
AB1096<br />
AB1097<br />
AB1098<br />
AB1099<br />
Guselkumab Provides Rapid Clinically Meaningful<br />
Improvements in Clinical and Patient Reported Outcomes<br />
and Sustained Disease Control of Psoriatic Arthritis<br />
J. Curtis<br />
Long-Term Efficacy of Guselkumab in Fatigue and Identification<br />
of Early Treatment Targets: Post Hoc Analysis Through 2 Years of<br />
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study<br />
Conducted in Biologic-Naïve Patients with Active Psoriatic Arthritis<br />
D. D. Gladman<br />
Early Clinical Improvement as Predictor of Long-Term<br />
Health-Related Quality of Life in Psoriatic Arthritis<br />
Patients Treated with Guselkumab: Post-Hoc Analysis<br />
Through 2 Years of A Phase-3 Study<br />
I. McInnes<br />
Bimekizumab Efficacy in High-Impact Areas for Patients with<br />
Moderate to Severe Plaque Psoriasis: Pooled Results Through<br />
Two Years from The Be Sure and Be Radiant Phase 3 Trials<br />
J. F. Merola<br />
Efficacy Of Upadacitinib in Patients with Psoriatic Arthritis<br />
Stratified by Involvement of Weight-Bearing Joint Regions:<br />
A Post Hoc Subgroup Analysis of The Phase 3, Randomized,<br />
Select-Psa 1 And Select-Psa 2 Trials<br />
K. Mizelle<br />
Guselkumab Rapidly Improves Activities of Daily Living in<br />
Patients with Active Psa: Pooled Analysis Of 2 Phase 3,<br />
Randomized, Placebo-Controlled Studies<br />
P. Rahman<br />
Long-Term Improvement in Individual ACR Response Criteria<br />
and Residual Disease in Psoriatic Arthritis Patients Treated with<br />
Guselkumab: Post Hoc Analysis of A Phase 3 Randomized,<br />
Double-Blind, Placebo-Controlled Study<br />
P. Nash<br />
Guselkumab Effect on Inflammatory Cardiovascular (CV)<br />
Risk Biomarkers, Efficacy, And Safety in Psoriatic Arthritis<br />
Patients with CV Risk Factors: Post-Hoc Analysis Of 2 Phase 3,<br />
Randomized, Double-Blind, Placebo-Controlled Studies<br />
A. Kavanaugh<br />
Improvement In Key Psoriatic Arthritis Core Domains with<br />
Guselkumab Treatment in An Enriched Population of Acr20 Non-<br />
Responders at Week 24: Post Hoc Analysis of Two Phase 3 Studies<br />
D. McGonagle<br />
Malignancies With Long-Term Use of Ixekizumab in Adults<br />
with Psoriasis, Psoriatic Arthritis, Or Axial Spondyloarthritis:<br />
A Post-hoc Analysis of Data From 25 Randomized Clinical Trials<br />
M. Lebwohl<br />
Deucravacitinib In Plaque Psoriasis: 2-Year Laboratory Results<br />
from The Phase 3 Poetyk Pso Program<br />
N. J. Korman<br />
Sustained Efficacy of Bimekizumab Treatment<br />
Assessed Using Composite Disease Activity<br />
Measures in Patients with Psoriatic Arthritis and Prior<br />
Inadequate Response or Intolerance to Tumour Necrosis<br />
Factor Inhibitors: Results from The Phase 3 Be Complete<br />
Study and Its Open Label Extension Up To 1 Year<br />
L. Coates<br />
H<br />
H<br />
AB1103<br />
AB1105<br />
AB1106<br />
AB1108<br />
AB1109<br />
AB1111<br />
AB1112<br />
AB1119<br />
AB1120<br />
AB1122<br />
AB1123<br />
AB1124<br />
AB1125<br />
Upadacitinib Real-Life Efficacy and Safety in Psoriatic Arthritis:<br />
Results At 24 Weeks of A Multicentric Italian Study (Up-Real)<br />
V. Paci<br />
Long-Term Safety of Ixekizumab Treatment in<br />
Adult Patients with Psoriasis, Psoriatic Arthritis,<br />
Or Axial Spondyloarthritis: A Post-Hoc Analysis Of<br />
End-Of-Study Program Data Relating To Major Adverse<br />
Cardiovascular Events<br />
M. Lebwohl<br />
Efficacy Of Risankizumab in Patients with Psoriatic Arthritis:<br />
A Systematic Review And Meta-Analysis<br />
H. Zhou<br />
Effect Of Guselkumab Administered Every 8 Weeks in Patients<br />
with Active Psoriatic Arthritis Persists Between Consecutive<br />
Doses and Is Durable: Post Hoc Analysis of A Phase 3,<br />
Randomized, Double-Blind, Placebo-Controlled Study<br />
P. J. Mease<br />
Treatment Retention and Safety of Ixekizumab in A Population<br />
with Psoriatic Arthritis Refractory to Biologic and Targeted<br />
Synthetic DMARDs<br />
I. Braña Abascal<br />
Sustained Response to Guselkumab Regardless of Baseline<br />
Demographic, Disease, And Medication Characteristics in<br />
Patients with Active Psoriatic Arthritis and An Inadequate<br />
Response to TNF Inhibitors: Results from A Phase 3b Trial<br />
I. McInnes<br />
Description of the Real-World Treatment Patterns of Guselkumab<br />
in The Management of Psoriatic Arthritis in Australia: An Analysis<br />
from The Opal Dataset<br />
G. Littlejohn<br />
Guselkumab Efficacy and Safety Analysis for Psa According<br />
to Baseline Characteristics as Gender, Obesity or Previous<br />
Treatment in Real Life After 52 Weeks<br />
V. Ruiz DEL Valle<br />
Real-Life Efficacy and Safety of Ixekizumab in<br />
A Cohort of Patients with Psoriatic Arthritis:<br />
A Single-Center Retrospective Study<br />
E. Bellis<br />
Guselkumab Vs Golimumab in Psa Tnfi-Inadequate Responders<br />
(Evolution): Formulating A Pragmatic Phase 3b Randomized Trial<br />
A. Ogdie<br />
Efficacy And Safety of Secukinumab in Patients with Psoriasis<br />
Q. Y. Su<br />
Tofacitinib In Psoriatic Arthritis -Well Tolerated Drug – Real Life<br />
Experience<br />
V. Petciappan<br />
Treatment With Upadacitinib in Refractory Psoriatic Arthritis.<br />
Multicenter Study Of 101 Patients of Clinical Practice<br />
E. Galíndez-Agirregoikoa<br />
H<br />
H<br />
Register for FREE content at www.cytokinesignalling.com<br />
DEVELOPED UNDER<br />
THE AUSPICES OF THE<br />
Follow us at:<br />
Cytokine Signalling Forum
Change language